Market Place
Sourcing Support
Amgen 1Q Results
21 May 2024 //
CONTRACT PHARMA
AMGEN to Submit Teprotumumab MAA to EMA
26 Apr 2024 //
PR NEWSWIRE
Amgen reports 3rd straight sequential sales increase for Tepezza
07 Feb 2024 //
FIERCE PHARMA
Analysis Highlights Adhering to Uninterrupted Full Course with TEPEZZA
29 Sep 2023 //
BUSINESSWIRE
Horizon adds `severe hearing impairment` warning to blockbuster`s label
20 Jul 2023 //
ENDPTS
Horizon`s Biologic Tepezza(teprotumumab) Receives Approval in the U.S.
17 Jul 2023 //
FDA
Viridian looks to beat Horizon`s Tepezza in thyroid eye disease
10 Jul 2023 //
FIERCE BIOTECH
TEPEZZA Approved in Brazil for the Treatment of Active TED
26 Jun 2023 //
PRESS RELEASE
New Data from TEPEZZA Trials Shed Light on Link Between Thyroid Autoimmunity and Hearing Risks
17 Jun 2023 //
PRESS RELEASE
Additional Data from Phase 4 TEPEZZA® Trial Presented at the Endocrine Society
17 Jun 2023 //
BUSINESSWIRE
Horizon Therapeutics plc Announces Data from the TEPEZZA
05 Jun 2023 //
BUSINESSWIRE
Horizon Announces Initiation of Ph3 Clinical Trial in Japan Evaluating TEPEZZA
01 May 2023 //
BUSINESSWIRE
Horizon Announces FDA Approval of Update to the Indication Language for TEPEZZA
14 Apr 2023 //
BUSINESSWIRE
Horizon Announces Positive Topline Data from TEPEZZA Phase 4 Clinical Trial
10 Apr 2023 //
BUSINESSWIRE
Real-World Experience Shows TEPEZZA Was Effective in Treating DON
12 Mar 2023 //
BUSINESSWIRE
Amgen dives deeper into rare disease drugs with $27.8 bln Horizon deal
13 Dec 2022 //
REUTERS
Horizon`s Biologic TEPEZZA (Teprotumumab) Receives Approval in the U.S.
06 Dec 2022 //
FDA
Xeris and Horizon enter partnership to develop teprotumumab
24 Nov 2022 //
PHARMACEUTICAL-TECHNOLOGY
Xeris Biopharma Announces Research Collaboration With Horizon Therapeutics
23 Nov 2022 //
BUSINESSWIRE
Horizon Therapeutics to Present New Data on TEPEZZA and TED at the ATA Meeting
13 Oct 2022 //
BUSINESSWIRE
Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA
29 Sep 2022 //
BUSINESSWIRE
Horizon lowers expectations for Tepezza, adjusts its strategy for year ahead
03 Aug 2022 //
ENDPTS
Analysis of Pooled Data from TEPEZZA Trials Reinforces Safety Profile in TED
11 Jun 2022 //
BUSINESSWIRE
Horizon Tx Initiates Phase 3 Trial (OPTIC-J) Evaluating Teprotumumab for TED
23 Feb 2022 //
BUSINESSWIRE
New PMS Analysis Shows Rate of Hearing-Related Events Associated with TEPEZZA
15 Feb 2022 //
BUSINESSWIRE
New Real-World Data Show High Rate of Patient Adherence to TEPEZZA for TED
12 Nov 2021 //
BUSINESSWIRE
New TEPEZZA Data to be Presented at the AAO 2021 Annual Meeting
12 Oct 2021 //
BUSINESSWIRE
New TEPEZZA® (teprotumumab-trbw) Data to be Presented (AAO)
12 Oct 2021 //
BUSINESSWIRE
Horizon Therapeutics plc Announces Purchase of Manufacturing Facility
17 Jun 2021 //
BUSINESSWIRE
Horizon Therapeutics plc Provides Preliminary 2020 Financial Results
11 Jan 2021 //
PRESS RELEASE
Horizon`s Tepezza supply dwindles as manufacturer Catalent pivots to Warp Speed vaccines
18 Dec 2020 //
FIERCE PHARMA
New Data Build on Growing Evidence Supporting TEPEZZA® (teprotumumab-trbw)
13 Nov 2020 //
BUSINESSWIRE
New TEPEZZA® (teprotumumab-trbw) Data to Be Presented at AAO
30 Oct 2020 //
BIOSPACE
AGC Biologics and Horizon Therapeutics plc Expand Partnership
29 Oct 2020 //
PRNEWSWIRE
Horizon Therapeutics plc Announces TEPEZZA® (teprotumumab-trbw)
20 Oct 2020 //
BUSINESSWIRE
Phase 3 Clinical Trial of TEPEZZA for Thyroid Eye Disease- NEJM
24 Jan 2020 //
BUSINESS WIRE
Horizon notches blockbuster FDA approval for rare eye disease med Tepezza
20 Jan 2020 //
FIERCE PHARMA
FDA expert panel unanimously recommends approval for Horizon eye drug
13 Dec 2019 //
ENDPTS
Horizon Therapeutics` Phase 3 trial finds `significant benefit` of teprotumumab
14 Oct 2019 //
SEEKINGAPLPHA
New Data from Teprotumumab Phase 3 OPTIC Study
12 Oct 2019 //
BIOSPECTRUMASIA
Horizon bulks up sales force ahead of $750M inflammatory eye drug launch
26 Jun 2019 //
FIERCE PHARMA
New Data from Phase 3 Teprotumumab Trial (OPTIC) or Eye Bulging TED
29 Apr 2019 //
BUSINESSWIRE
New phase 3 data paints fuller picture for Horizon’s teprotumumab
26 Apr 2019 //
FIERCE BIOTECH
Horizon sunny as thyroid eye disease drug hits the mark
05 Mar 2019 //
PMLIVE
After thyroid eye drug scores PhIII test, Horizon readies marketing application
01 Mar 2019 //
ENDPTS
